ArticleInflammopharmacology2026
Therapeutic potential of Celtis eriocarpa Decne.: in vivo and in vitro antiarthritic effects supported by GC‒MS and qRT‒PCR analysis.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis is an autoimmune disorder characterized by cartilage destruction, joint inflammation, and systemic complications. Incomplete disease remission, adverse effects, and limited treatment availability underscore the need for novel therapeutic interventions. With this ultimate goal, the aim of the current study was to assess the anti-inflammatory and antiarthritic potential of chloroform and ethanol extracts of Celtis eriocarpa Decne. Gas chromatography coupled with mass spectrometry (GC-MS) analysis of these extracts revealed the presence of diverse bioactive compounds with well-recognized anti-inflammatory and antiarthritic activities, including phytol, neophytadiene, tocopherols, hexadecenoic acid methyl ester, squalene, and 2-tert-butylphenol derivatives. In vitro assays demonstrated significant, dose-dependent inhibition of protein denaturation by these extracts, with the activity of the chloroform fraction comparable to that of the diclofenac sodium standard. In vivo studies in a formaldehyde-induced arthritis rat model revealed significantly reduced paw edema and arthritis scores and improved mobility after oral administration of Celtis eriocarpa chloroform extracts (CE). Radiographic analysis further confirmed joint preservation in a rat model treated with CE. Histopathological assessments indicated marked reductions in synovial hyperplasia, cartilage erosion, and inflammatory cell infiltration, specifically in the high-dose CE groups. Finally, hematological and biochemical evaluations revealed normalization of inflammatory markers, downregulation of the expression levels of key proinflammatory cytokines (TNF-α, IL-6, NF-κB, IL-1β, and COX-2), and upregulation of the expression levels of anti-inflammatory cytokines (IL-4 and IL-10). Collectively, these findings demonstrate that Celtis eriocarpa extracts are enriched in bioactive phytoconstituents and hold substantial potential as therapeutic candidates for the management of rheumatoid arthritis and inflammatory disorders.
Indexed as
Identifiers
41703365What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.